Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2006

Open Access 01-08-2006 | Research article

The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus

Authors: Ruth Fritsch-Stork, Daniela Müllegger, Karl Skriner, Beatrice Jahn-Schmid, Josef S Smolen, Günter Steiner

Published in: Arthritis Research & Therapy | Issue 4/2006

Login to get access

Abstract

A hallmark of systemic lupus erythematosus (SLE) is the appearance of autoantibodies to nuclear antigens, including autoantibodies directed to the heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2), which occur in 20% to 30% of SLE patients as well as in animal models of this disease. To investigate the underlying cellular reactivity and to gain further insight into the nature and potential pathogenic role of this autoimmune response we characterized the T cell reactivity against hnRNP-A2 in patients with SLE in comparison to healthy controls. Cellular proliferation of peripheral blood T cells to hnRNP-A2 was determined by [3H]thymidine incorporation and T cell clones (TCCs) specific for hnRNP-A2 were grown by limiting dilution cloning; IFNγ, IL-4 and IL-10 in culture supernatants were measured by ELISA. Bioactivity of culture supernatants was determined by incubation of anti-CD3/anti-CD28 stimulated peripheral blood CD4+ T cells with supernatants of TCCs. Stimulation assays performed with peripheral blood mononuclear cells of 35 SLE patients and 21 healthy controls revealed pronounced proliferative responses in 66% of SLE patients and in 24% of the controls, which were significantly higher in SLE patients (p < 0.00002). Furthermore, hnRNP-A2 specific TCCs generated from SLE patients (n = 22) contained a relatively high proportion of CD8+ clones and mostly lacked CD28 expression, in contrast to TCCs derived from healthy controls (n = 12). All CD4+ TCCs of patients and all control TCCs secreted IFNγ and no IL-4. In contrast, CD8+ TCCs of patients secreted very little IFNγ, while production of IL-10 did not significantly differ from other T cell subsets. Interestingly, all CD8+ clones producing IL-10 in large excess over IFNγ lacked expression of CD28. Functional assays showed a stimulatory effect of the supernatants derived from these CD8+CD28- hnRNP-A2 specific TCCs that was similar to that of CD4+CD28+ clones. Taken together, the pronounced peripheral T cell reactivity to hnRNP-A2 observed in the majority of SLE patients and the distinct phenotype of patient-derived CD8+ TCCs suggest a role for these T cells in the pathogenesis of SLE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthritis Rheum. 1982, 25: 1271-1277.CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthritis Rheum. 1982, 25: 1271-1277.CrossRefPubMed
2.
go back to reference Pisetsky DS: Anti-DNA and autoantibodies. Curr Opin Rheumatol. 2000, 12: 364-368. 10.1097/00002281-200009000-00002.CrossRefPubMed Pisetsky DS: Anti-DNA and autoantibodies. Curr Opin Rheumatol. 2000, 12: 364-368. 10.1097/00002281-200009000-00002.CrossRefPubMed
3.
go back to reference Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J: The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum. 2000, 43: 420-428. 10.1002/1529-0131(200002)43:2<420::AID-ANR24>3.0.CO;2-Z.CrossRefPubMed Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J: The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum. 2000, 43: 420-428. 10.1002/1529-0131(200002)43:2<420::AID-ANR24>3.0.CO;2-Z.CrossRefPubMed
5.
go back to reference Reyes PA, Tan EM: DNA-binding property of Sm nuclear antigen. J Exp Med. 1977, 145: 749-754. 10.1084/jem.145.3.749.CrossRefPubMed Reyes PA, Tan EM: DNA-binding property of Sm nuclear antigen. J Exp Med. 1977, 145: 749-754. 10.1084/jem.145.3.749.CrossRefPubMed
6.
go back to reference Holyst MM, Hill DL, Hoch SO, Hoffmann RW: Analysis of T and B cell responses against U small nuclear ribonucleoprotein 70-kD, B and D polypeptides among patients with systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum. 1997, 40: 1493-1503.CrossRefPubMed Holyst MM, Hill DL, Hoch SO, Hoffmann RW: Analysis of T and B cell responses against U small nuclear ribonucleoprotein 70-kD, B and D polypeptides among patients with systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum. 1997, 40: 1493-1503.CrossRefPubMed
7.
go back to reference Steiner G, Hartmuth , Skriner K, Maurer-Fogy I, Sinski A, Hassfeld W, Barta A, Smolen JS: Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest. 1992, 90: 1061-1066.PubMedCentralCrossRefPubMed Steiner G, Hartmuth , Skriner K, Maurer-Fogy I, Sinski A, Hassfeld W, Barta A, Smolen JS: Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest. 1992, 90: 1061-1066.PubMedCentralCrossRefPubMed
8.
go back to reference Hassfeld W, Steiner G, Studnicka-Benke A, Skriner K, Graninger W, Fischer I, Smolen JS: Autoimmune response to the spliceosome: an immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum. 1995, 38: 777-785.CrossRefPubMed Hassfeld W, Steiner G, Studnicka-Benke A, Skriner K, Graninger W, Fischer I, Smolen JS: Autoimmune response to the spliceosome: an immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum. 1995, 38: 777-785.CrossRefPubMed
9.
go back to reference Steiner G, Skriner K, Smolen JS: Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int Arch Allergy Immunol. 1996, 111: 314-319.CrossRefPubMed Steiner G, Skriner K, Smolen JS: Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int Arch Allergy Immunol. 1996, 111: 314-319.CrossRefPubMed
10.
go back to reference Skriner K, Sommergruber WH, Tremmel V, Fischer I, Barta A, Smolen JS, Steiner G: Anti-hnRNP-A2 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex: differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J Clin Invest. 1997, 100: 127-135.PubMedCentralCrossRefPubMed Skriner K, Sommergruber WH, Tremmel V, Fischer I, Barta A, Smolen JS, Steiner G: Anti-hnRNP-A2 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex: differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J Clin Invest. 1997, 100: 127-135.PubMedCentralCrossRefPubMed
11.
go back to reference Dumortier H, Monneaux F, Jahn-Schmid B, Briand JP, Skriner K, Cohen PL, Smolen JS, Steiner G, Muller S: B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J Immunol. 2000, 165: 2297-2305.CrossRefPubMed Dumortier H, Monneaux F, Jahn-Schmid B, Briand JP, Skriner K, Cohen PL, Smolen JS, Steiner G, Muller S: B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J Immunol. 2000, 165: 2297-2305.CrossRefPubMed
12.
go back to reference Hayer S, Tohidast-Akrad M, Haralambous S, Jahn-Schmid B, Skriner K, Trembleau S, Dumortier H, Pinol-Roma S, Redlich K, Schett G, et al: Aberrant expression of the autoantigen hnRNP-A2/B1 (RA33) and spontaneous formation of rheumatoid arthritis associated anti-RA33 autoantibodies in TNFα transgenic mice. J Immunol. 2005, 175: 8327-8336.CrossRefPubMed Hayer S, Tohidast-Akrad M, Haralambous S, Jahn-Schmid B, Skriner K, Trembleau S, Dumortier H, Pinol-Roma S, Redlich K, Schett G, et al: Aberrant expression of the autoantigen hnRNP-A2/B1 (RA33) and spontaneous formation of rheumatoid arthritis associated anti-RA33 autoantibodies in TNFα transgenic mice. J Immunol. 2005, 175: 8327-8336.CrossRefPubMed
13.
go back to reference Weighardt F, Biamonti G, Riva S: The roles of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA metabolism. Bioessays. 1996, 18: 747-756. 10.1002/bies.950180910.CrossRefPubMed Weighardt F, Biamonti G, Riva S: The roles of heterogeneous nuclear ribonucleoproteins (hnRNP) in RNA metabolism. Bioessays. 1996, 18: 747-756. 10.1002/bies.950180910.CrossRefPubMed
14.
go back to reference Krecic AM, Swanson MS: HnRNP complexes: composition, structure, and function. Curr Opin Cell Biol. 1999, 11: 363-371. 10.1016/S0955-0674(99)80051-9.CrossRefPubMed Krecic AM, Swanson MS: HnRNP complexes: composition, structure, and function. Curr Opin Cell Biol. 1999, 11: 363-371. 10.1016/S0955-0674(99)80051-9.CrossRefPubMed
15.
go back to reference Mayeda A, Munroe SH, Caceres JF, Krainer AR: Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 1994, 13: 5483-5495.PubMedCentralPubMed Mayeda A, Munroe SH, Caceres JF, Krainer AR: Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 1994, 13: 5483-5495.PubMedCentralPubMed
16.
go back to reference Carson JH, Kwon S, Barbarese E: RNA trafficking in myelinating cells. Curr Opin Neurobiol. 1998, 8: 607-612. 10.1016/S0959-4388(98)80088-3.CrossRefPubMed Carson JH, Kwon S, Barbarese E: RNA trafficking in myelinating cells. Curr Opin Neurobiol. 1998, 8: 607-612. 10.1016/S0959-4388(98)80088-3.CrossRefPubMed
17.
go back to reference Kamma H, Horiguchi H, Wan L, Matsui M, Fujiwara M, Fujimoto M, Yazawa T, Dreyfuss G: Molecular characterization of the hnRNP A2/B1 proteins: tissue-specific expression and novel isoforms. Exp Cell Res. 1999, 246: 399-411. 10.1006/excr.1998.4323.CrossRefPubMed Kamma H, Horiguchi H, Wan L, Matsui M, Fujiwara M, Fujimoto M, Yazawa T, Dreyfuss G: Molecular characterization of the hnRNP A2/B1 proteins: tissue-specific expression and novel isoforms. Exp Cell Res. 1999, 246: 399-411. 10.1006/excr.1998.4323.CrossRefPubMed
18.
go back to reference Smolen JS, Klippel JH, Penner E, Reichlin M, Steinberg AD, Chused TM, Scherak O, Graninger W, Hartter E, Zielinski CC, et al: HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody reponses to nuclear antigens. Ann Rheum Dis. 1987, 46: 457-462.PubMedCentralCrossRefPubMed Smolen JS, Klippel JH, Penner E, Reichlin M, Steinberg AD, Chused TM, Scherak O, Graninger W, Hartter E, Zielinski CC, et al: HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody reponses to nuclear antigens. Ann Rheum Dis. 1987, 46: 457-462.PubMedCentralCrossRefPubMed
19.
go back to reference Stephens HA, McHugh NJ, Maddison PJ, Isenberg DA, Welsh KI, Panayi GS: HLA class II restriction of autoantibody production in patients with systemic lupus erythematosus. Immunogengetics. 1991, 33: 276-280. Stephens HA, McHugh NJ, Maddison PJ, Isenberg DA, Welsh KI, Panayi GS: HLA class II restriction of autoantibody production in patients with systemic lupus erythematosus. Immunogengetics. 1991, 33: 276-280.
20.
go back to reference Mohan C, Adams S, Stanik V, Datta SK: Nuclesosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med. 1993, 177: 1367-1381. 10.1084/jem.177.5.1367.CrossRefPubMed Mohan C, Adams S, Stanik V, Datta SK: Nuclesosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med. 1993, 177: 1367-1381. 10.1084/jem.177.5.1367.CrossRefPubMed
21.
go back to reference Voll RE, Roth EA, Girkontaite I, Fehr H, Herrmann M, Lorenz HM, Kalden JR: Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum. 1997, 40: 2162-2172.CrossRefPubMed Voll RE, Roth EA, Girkontaite I, Fehr H, Herrmann M, Lorenz HM, Kalden JR: Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum. 1997, 40: 2162-2172.CrossRefPubMed
22.
go back to reference Converso M, Bertero MT, Vallario A, Caligaris-Cappio F: Analysis of T-cell clones in systemic lupus erythematosus. Haematologica. 2000, 85: 118-123.PubMed Converso M, Bertero MT, Vallario A, Caligaris-Cappio F: Analysis of T-cell clones in systemic lupus erythematosus. Haematologica. 2000, 85: 118-123.PubMed
23.
go back to reference Talken BL, Bailey CW, Reardon SL, Caldwell CW, Hoffman RW: Structural analysis of TCRalpha and beta chains from human T-Cell clones specific for small nuclear ribonucleoprotein polypeptides Sm-D, Sm-B and U1–70 kDa: TCR complementarity determining region 3 usage appears highly conserved. Scand J Immunol. 2001, 54: 204-210. 10.1046/j.1365-3083.2001.00930.x.CrossRefPubMed Talken BL, Bailey CW, Reardon SL, Caldwell CW, Hoffman RW: Structural analysis of TCRalpha and beta chains from human T-Cell clones specific for small nuclear ribonucleoprotein polypeptides Sm-D, Sm-B and U1–70 kDa: TCR complementarity determining region 3 usage appears highly conserved. Scand J Immunol. 2001, 54: 204-210. 10.1046/j.1365-3083.2001.00930.x.CrossRefPubMed
24.
go back to reference Greidinger EL, Gazitt T, Jaimes KF, Hoffman RW: Human T cell clones specific for heterogeneous nuclear ribonucleoprotein A2 autoantigen from connective tissue disease patients assist in autoantibody production. Arthritis Rheum. 2004, 50: 2216-2222. 10.1002/art.20287.CrossRefPubMed Greidinger EL, Gazitt T, Jaimes KF, Hoffman RW: Human T cell clones specific for heterogeneous nuclear ribonucleoprotein A2 autoantigen from connective tissue disease patients assist in autoantibody production. Arthritis Rheum. 2004, 50: 2216-2222. 10.1002/art.20287.CrossRefPubMed
25.
go back to reference Gebhard KL, Veldman CM, Wassmuth R, Schultz E, Schuler G, Hertl M: Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals. Exp Dermatol. 2005, 14: 586-592. 10.1111/j.0906-6705.2005.00329.x.CrossRefPubMed Gebhard KL, Veldman CM, Wassmuth R, Schultz E, Schuler G, Hertl M: Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals. Exp Dermatol. 2005, 14: 586-592. 10.1111/j.0906-6705.2005.00329.x.CrossRefPubMed
26.
go back to reference Diaz-Villoslada P, Shih A, Shao L, Genain CP, Hauser SL: Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen. J Neuroimmunol. 1999, 99: 36-43. 10.1016/S0165-5728(99)00099-5.CrossRefPubMed Diaz-Villoslada P, Shih A, Shao L, Genain CP, Hauser SL: Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen. J Neuroimmunol. 1999, 99: 36-43. 10.1016/S0165-5728(99)00099-5.CrossRefPubMed
27.
go back to reference Fritsch R, Eselbock D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast-Akrad M, Hayer S, Neumuller J, Pinol-Roma S, et al: Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol. 2002, 169: 1068-1076.CrossRefPubMed Fritsch R, Eselbock D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast-Akrad M, Hayer S, Neumuller J, Pinol-Roma S, et al: Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol. 2002, 169: 1068-1076.CrossRefPubMed
28.
go back to reference Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 549-554.PubMed Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 549-554.PubMed
29.
go back to reference Scheinecker C, Machold KP, Majdic O, Hocker P, Knapp W, Smolen JS: Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells. J Immunol. 1998, 161: 3966-3973.PubMed Scheinecker C, Machold KP, Majdic O, Hocker P, Knapp W, Smolen JS: Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells. J Immunol. 1998, 161: 3966-3973.PubMed
30.
go back to reference Fritsch R, Bohle B, Vollmann U, Wiedermann U, Jahn-Schmid B, Krebitz M, Breiteneder H, Kraft D, Ebner C: Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol. 1998, 102: 679-686. 10.1016/S0091-6749(98)70287-8.CrossRefPubMed Fritsch R, Bohle B, Vollmann U, Wiedermann U, Jahn-Schmid B, Krebitz M, Breiteneder H, Kraft D, Ebner C: Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol. 1998, 102: 679-686. 10.1016/S0091-6749(98)70287-8.CrossRefPubMed
31.
go back to reference Isenberg DA, Steiner G, Smolen JS: Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol. 1994, 21: 1260-1263.PubMed Isenberg DA, Steiner G, Smolen JS: Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol. 1994, 21: 1260-1263.PubMed
32.
go back to reference Richter-Cohen M, Steiner G, Smolen JS, Isenberg DA: Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subgroup. Br J Rheumatol. 1998, 37: 421-424. 10.1093/rheumatology/37.4.421.CrossRefPubMed Richter-Cohen M, Steiner G, Smolen JS, Isenberg DA: Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subgroup. Br J Rheumatol. 1998, 37: 421-424. 10.1093/rheumatology/37.4.421.CrossRefPubMed
33.
go back to reference Smolen JS, Chused TM, Leiserson WN, Reeves JP, Alling D, Steinberg AD: Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Am J Med. 1982, 72: 783-790. 10.1016/0002-9343(82)90544-7.CrossRefPubMed Smolen JS, Chused TM, Leiserson WN, Reeves JP, Alling D, Steinberg AD: Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Am J Med. 1982, 72: 783-790. 10.1016/0002-9343(82)90544-7.CrossRefPubMed
34.
go back to reference Bakke AC, Kirkland PA, Kitridou RC, Quismorio FP, Rea T, Ehresmann GR, Horwitz AD: T lymphocyte subsets in systemic lupus erythematosus. Arthritis Rheum. 1983, 26: 745-750.CrossRefPubMed Bakke AC, Kirkland PA, Kitridou RC, Quismorio FP, Rea T, Ehresmann GR, Horwitz AD: T lymphocyte subsets in systemic lupus erythematosus. Arthritis Rheum. 1983, 26: 745-750.CrossRefPubMed
35.
go back to reference Maeda N, Sekigawa I, Matsumoto M, Hashimoto H, Hirose S: Relationship between CD4+/CD8+ T cell ratio and T cell activation in systemic lupus erythematosus. Scand J Rheumatol. 1999, 28: 166-170. 10.1080/03009749950154248.CrossRefPubMed Maeda N, Sekigawa I, Matsumoto M, Hashimoto H, Hirose S: Relationship between CD4+/CD8+ T cell ratio and T cell activation in systemic lupus erythematosus. Scand J Rheumatol. 1999, 28: 166-170. 10.1080/03009749950154248.CrossRefPubMed
36.
go back to reference Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M, Setti M, Puppo F, Indiveri F: Impairment of CD8+ T suppressor cell function in patients with active Systemic Lupus Erythmatosus. J Immunol. 2001, 166: 6452-6457.CrossRefPubMed Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M, Setti M, Puppo F, Indiveri F: Impairment of CD8+ T suppressor cell function in patients with active Systemic Lupus Erythmatosus. J Immunol. 2001, 166: 6452-6457.CrossRefPubMed
37.
go back to reference Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, et al: Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol. 2004, 65: 142-156. 10.1016/j.humimm.2003.12.001.CrossRefPubMed Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, et al: Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol. 2004, 65: 142-156. 10.1016/j.humimm.2003.12.001.CrossRefPubMed
38.
go back to reference Liu Z, Tugulea S, Cortesini R, Suciu-Foca N: Specific suppression of T helper alloreactivity by allo-MHC class I restriced CD8+CD28- T cells. Int Immunol. 1998, 10: 775-783. 10.1093/intimm/10.6.775.CrossRefPubMed Liu Z, Tugulea S, Cortesini R, Suciu-Foca N: Specific suppression of T helper alloreactivity by allo-MHC class I restriced CD8+CD28- T cells. Int Immunol. 1998, 10: 775-783. 10.1093/intimm/10.6.775.CrossRefPubMed
39.
go back to reference Colovai AI, Liu Z, Ciubotariu R, Lederman S, Cortesini R, Suciu-Foca N: Induction of xenoreactive CD4-T cell anergy by suppressor CD8+CD28- Tcells. Transplantation. 2000, 69: 1304-1310. 10.1097/00007890-200004150-00016.CrossRefPubMed Colovai AI, Liu Z, Ciubotariu R, Lederman S, Cortesini R, Suciu-Foca N: Induction of xenoreactive CD4-T cell anergy by suppressor CD8+CD28- Tcells. Transplantation. 2000, 69: 1304-1310. 10.1097/00007890-200004150-00016.CrossRefPubMed
40.
go back to reference Najafian N, Chitnis T, Salama AD, Zhu B, Benou C, Yuan X, Clarkson MR, Sayegh MH, Khoury SJ: Regulatory functions of CD8+CD28- T cells in an auoimmune disease mode. J Clin Invest. 2003, 112: 1037-1048. 10.1172/JCI200317935.PubMedCentralCrossRefPubMed Najafian N, Chitnis T, Salama AD, Zhu B, Benou C, Yuan X, Clarkson MR, Sayegh MH, Khoury SJ: Regulatory functions of CD8+CD28- T cells in an auoimmune disease mode. J Clin Invest. 2003, 112: 1037-1048. 10.1172/JCI200317935.PubMedCentralCrossRefPubMed
41.
go back to reference Vallejo AN: CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev. 2005, 205: 158-169. 10.1111/j.0105-2896.2005.00256.x.CrossRefPubMed Vallejo AN: CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev. 2005, 205: 158-169. 10.1111/j.0105-2896.2005.00256.x.CrossRefPubMed
42.
go back to reference Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC: Serum IL-10 titres in systemic lupus erythematosus reflect disease activity. Lupus. 1995, 4: 393-395.CrossRefPubMed Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC: Serum IL-10 titres in systemic lupus erythematosus reflect disease activity. Lupus. 1995, 4: 393-395.CrossRefPubMed
43.
go back to reference Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, Galanaud P, Emilie D: In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. Arthritis Rheum. 1994, 37: 1647-1656.CrossRefPubMed Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, Galanaud P, Emilie D: In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. Arthritis Rheum. 1994, 37: 1647-1656.CrossRefPubMed
44.
go back to reference Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D: Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995, 181: 839-844. 10.1084/jem.181.3.839.CrossRefPubMed Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D: Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995, 181: 839-844. 10.1084/jem.181.3.839.CrossRefPubMed
Metadata
Title
The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
Authors
Ruth Fritsch-Stork
Daniela Müllegger
Karl Skriner
Beatrice Jahn-Schmid
Josef S Smolen
Günter Steiner
Publication date
01-08-2006
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2006
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2007

Other articles of this Issue 4/2006

Arthritis Research & Therapy 4/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine